- Announced positive data from interim analysis of Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy; data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving cisplatin chemotherapy for cancer -
Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here